Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

This is a Phase III, randomized, placebo controlled study evaluating the efficacy and safety of depemokimab in patients with COPD GOLD E and elevated eosinophils.

Depemokimab is monoclonal antibody selectively binding to interleukin-5 which is a central driver of eosinophilic inflammation in airway diseases. It is an ultra-long-acting biologic, allowing for dosing as infrequently as twice yearly by providing sustained inhibition of IL-5 and continuous reduction of eosinophil counts.

Primary End-Points:
  • Annualized rate of moderate/severe exacerbations
Key inclusion criteria are:
  • COPD GOLD E
  • Elevated eosinophils
  • On triple inhaler therapy
ClinicalTrials.gov Identifier: NCT06959095

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!